Tredje AP fonden Sells 3,851 Shares of Labcorp Holdings Inc. $LH

Tredje AP fonden lowered its holdings in shares of Labcorp Holdings Inc. (NYSE:LH) by 28.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,497 shares of the medical research company’s stock after selling 3,851 shares during the period. Tredje AP fonden’s holdings in Labcorp were worth $2,726,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SP Asset Management LLC increased its stake in Labcorp by 0.3% in the second quarter. SP Asset Management LLC now owns 14,177 shares of the medical research company’s stock valued at $3,722,000 after acquiring an additional 38 shares during the period. HBK Sorce Advisory LLC boosted its holdings in Labcorp by 4.3% during the third quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company’s stock valued at $254,000 after purchasing an additional 38 shares in the last quarter. Pure Financial Advisors LLC grew its stake in shares of Labcorp by 3.9% in the 3rd quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company’s stock valued at $292,000 after purchasing an additional 38 shares during the period. Zions Bancorporation National Association UT grew its stake in shares of Labcorp by 21.9% in the 2nd quarter. Zions Bancorporation National Association UT now owns 223 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 40 shares during the period. Finally, Hantz Financial Services Inc. raised its holdings in shares of Labcorp by 48.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock worth $35,000 after buying an additional 40 shares in the last quarter. 95.94% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on LH shares. Robert W. Baird upped their price target on Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research report on Wednesday. JPMorgan Chase & Co. increased their target price on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research report on Wednesday. UBS Group cut their price target on shares of Labcorp from $325.00 to $320.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. Weiss Ratings raised shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Finally, Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Ten analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $302.75.

Insider Transactions at Labcorp

In other news, EVP Jonathan C. Meltzer sold 87 shares of Labcorp stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total transaction of $25,266.54. Following the completion of the sale, the executive vice president owned 2,782 shares in the company, valued at $807,948.44. The trade was a 3.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Adam H. Schechter sold 5,273 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $284.38, for a total transaction of $1,499,535.74. Following the sale, the chief executive officer directly owned 87,343 shares of the company’s stock, valued at approximately $24,838,602.34. This trade represents a 5.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.84% of the stock is owned by company insiders.

Labcorp Trading Up 0.0%

LH opened at $282.57 on Friday. Labcorp Holdings Inc. has a 1-year low of $209.38 and a 1-year high of $293.72. The stock has a market capitalization of $23.43 billion, a PE ratio of 27.01, a PEG ratio of 1.93 and a beta of 1.03. The company has a current ratio of 1.42, a quick ratio of 1.35 and a debt-to-equity ratio of 0.60. The firm has a 50-day moving average price of $265.50 and a two-hundred day moving average price of $269.25.

Labcorp (NYSE:LH) last released its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, beating the consensus estimate of $3.95 by $0.12. The business had revenue of $3.52 billion for the quarter, compared to analysts’ expectations of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. Labcorp’s revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.45 earnings per share. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, equities analysts anticipate that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. Labcorp’s payout ratio is presently 27.53%.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.